Kardiorespirator tadqiqotlar jurnali 1.(2020)
Subject of the article
СОСТОЯНИЕ КАРДИОРЕСПИРАТОРНОЙ СИСТЕМЫ У ПАЦИЕНТОВ С ГИПЕРТРОФИЧЕСКОЙ КАРДИОМИОПАТИЕЙ (16-22)
Authors
Бокерия Л.А., Глушко Л.А.
Institution
ФГБУ “НМИЦ ССХ им.А.Н.Бакулева” МЗ РФ
Abstract
Гипертрофическая кардиомиопатия является наиболее распространенным наследственным заболеванием сердца, распространенность которого оценивается в 1 на 500 в общей популяции. Данное аутосомно-доминантное заболевание характеризуется утолщением стенки левого и изредка правого желудочка. Применение кардиореспираторного нагрузочного тестирования помогает в оценке тяжести хронической сердечной недостаточности и функциональных возможностей пациентов с гипертрофической кардиомиопатией, для прогнозирования рисков кардиореспираторных осложнений заболевания и выявления механизмов функциональных ограничений. В данной статье подробно описывается функциональная способность и нагрузочные тесты кардиореспираторной системы при гипертрофической кардиомиопатии. Кардиореспираторное нагрузочное тестирование обеспечивает неинвазивный и безопасный подход для оценки функционального состояния кардиореспираторной системы у пациентов с гипертрофической кардиомиопатией возможностей, помогая понять основные патофизиологические механизмы течения заболевания. Данный неинвазивный метод оценки позволяет стратифицировать пациента с гипертрофической кардиомиопатией в отношении рисков сердечно- сосудистой смертности и заболеваемости, а также своевременно направлять на специфические методы лечения.
Key words
гипертрофическая кардиомиопатия, кардиореспираторная система, кардиореспираторное нагрузочное тестирования.
Literature
Adler A. Natural History of Hypertrophic Cardiomyopathy. In.Naidu S. (eds) Hypertrophic Cardiomyopathy. Springer, Cham.-2019. 2. Agostoni P. MECKI Score Research Group. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. Int J Cardiol 2013;167(6):2710-8. 3. Agostoni P. Work-rate affects cardiopulmonary exercise test results in heart failure. Eur J Heart Fail 2005;7(4):498-504. 4. Anastasakis A.Similarities in the profile of cardiopulmonary exercise testing between patients with hypertrophic cardiomyopathy and strength athletes. Heart 2005;91(11):1477-8. 5. Arena R. Ventilatory efficiency and resting emodynamics in hypertrophic cardiomyopathy. Med Sci Sports Exerc 2008;40(5):799-805. 6. Arshad W. Systole-diastole mismatch in hypertrophic cardiomyopathy is caused by stress induced left ventricular outflow tract obstruction. Am Heart J 2004;148:903-9. 7. Balke B. An experimental study of physical fitness of air force personnel. US Armed Forces Med J 1959;10:675-88. 8. Belardinelli R. Exerciseinduced myocardial ischaemia detected by cardiopulmonary exercise testing. Eur Heart J 2003;24(14):1304-13. 9. Coats C.J. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. Circ Heart Fail 2015;8:1022- 31. 10. Cohen-Solal A .A non-invasively determined surrogate of cardiac power ('circulatory power') at peak exercise is a powerful prognostic factor in chronic heart failure. Eur Heart J 2002;23(10):806-14. 11. Corrà U. Exercise haemodynamic variables rather than ventilatory efficiency indexes contribute to risk assessment in chronic heart failure patients treated with carvedilol. Eur Heart J 2009;30(24):3000-6. 12. Critoph CH. Cardiac output response and peripheral oxygen extraction during exercise among symptomatic hypertrophic cardiomyopathy patients with and without left ventricular outflow tract obstruction. Heart 2014;100(8):639-46. 13. Dass S. Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction. Eur Heart J 2015;36(24):1547-54. 14. Efthimiadis G.K. Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy. Int J Cardiol 2011;153:179-84. 15. Elliott P.M. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-79. 16. Finocchiaro G. Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. JACC Heart Fail 2015;3:408-18. 17. Fletcher G.F. American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation 2013;128(8):873-934. 18. Gersh B.J. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; HF Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:2761-96. 19. Guazzi M. Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. J Am CollCardiol 2005;46(10):1883-90. 20. Guazzi M. Cardiopulmonary exercise testing reflects similar pathophysiology and disease severity in heart failure patients with reduced and preserved ejection fraction. Eur J Prev Cardiol 2014;21(7):847-54. 21. Guazzi M. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation 2012;126:2261-74. 22. Jones S. Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart 1998;80:60-7. 23. Khitrova M., Bokeriya L.A., Glushko L.A., Berseneva M.I., Plavinskij S.L., Avdeeva M.V., Abdurazakov M.A. Metaanalysis of results the surgical treatment hypertrophic obstructive cardiomyopathy. В книге: The 26th Annual Meeting of the Asian Society for Cardiovascular and Thoracic Surgery conference proceedings. 2018. С. 235. 24. Lele S.S. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume, heart rate, and diastolic filling characteristics. Circulation 1995;92:2886-94. 25. Luo H.C. Exercise heart rates in patients with hypertrophic cardiomyopathy. Am J Cardiol 2015;15;115(8):1144-50. 26. Magrì D. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. Heart 2016;102(8):602-9. 27. Magrì D. Cardiovascular mortality and chronotropic incompetence in systolic heart failure: the importance of a reappraisal of current cut-off criteria. Eur J Heart Fail 2014;16(2):201-9. 28. Magrì D. Chronotropic incompetence and functional capacity in chronic heart failure: no role of beta-blockers and betablocker dose. CardiovascTher 2012;30:100-8. 29. Magrì D. Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: a single-center study. Intern Emerg Med 2014;9:293-302. 30. Magrì D. Heart Failure Progression in Hypertrophic Cardiomyopathy - Possible Insights From Cardiopulmonary Exercise Testing. Circ J 2016;80:2204-11. 31. Magrì D. Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) Score Research Group. Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. Eur J Prev Cardiol 2015;22(8):1046-55. 32. Maron B.J. Hypertrophic cardiomyopathy. Lancet 2013;381:242 – 255. Maron B.J. Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014;64:83-99. 34. Marstrand P. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation. 2020; 141(17):1371-1383. 35. Masri A. Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. Am Heart J 2015;169:684-92. 36. Myers J. Comparison of the ramp versus standard exercise protocols. J Am CollCardiol 1991;17(6):1334-42. 37. Ong K.C. Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2016;17(6):604-10. 38. Patel V. Mechanisms and medical management of exercise intolerance in hypertrophic cardiomyopathy. Curr Pharm Des2015;21(4):466-72. 39. Re F. Dissecting functional impairment in hypertrophic cardiomyopathy by dynamic assessment of diastolic reserve and outflow obstruction: A combined cardiopulmonary-echocardiographic study. Int J Cardiol 2016;S0167-5273(16)33229-6. 40. Schumacker P.T. Oxygen delivery and uptake by peripheral tissues: physiology and pathophysiology. Crit Care Clin 1989;5(2):255-69. 41. Sharma S. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol 2000;86:162-8. 42. Sharma S. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 2000;36(3):864-70. 43. Singh K. A meta-analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter CardiovascInterv. 2016;88(1):107-15. 44. Skalski J. The Safety of Cardiopulmonary Exercise Testing in a Population with High-Risk Cardiovascular Diseases. Circulation 2012;126:2465-72. 45. Swaminathan P.D. Oxidized CaMKII causes cardiac sinus node dysfunction in mice. J Clin Invest 2011;121(8):3277-88. 46. Valeti U.S. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007;49(3):350-7. 47. Wasserman K. Principles of exercise testing and interpretation. 5th ed. Baltimore: Lippincott Williams & Wilkins 2012;71- 180. 48. Ивлева О.В., Берсенева М.И., Косарева Т.И., Хитрова М.Э., Щебуняева Е.А.Структурно-геометрические особенности сердца у больных с обструктивной гипертрофической кардиомиопатией. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2019. Т. 20. № S5. С. 119. 49. Маленков А.Д., Берсенева М.И., Косарева Т.И., Бокерия Л.А. Митральная недостаточность у пациентов с гипертрофической обструктивной кардиомиопатией: анализ геометрии митрального клапана по данным 3D ЧПЭХОКГ. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2017. Т. 18. № S3. С. 94. 50. Самерханова Л.Н., Берсенева М.И., Ивлева О.В., Хитрова М.Э., Маленков Д.А.Оценка диастолической функции сердца у больных ГКМП без обструкции выводного отдела на фоне приема бета-блока